Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Shares Outstanding (Weighted Average) (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $49.9 million as the latest value for Q2 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 2.45% to $49.9 million in Q2 2025 year-over-year; TTM through Jun 2025 was $49.9 million, a 2.45% increase, with the full-year FY2024 number at $48.8 million, changed N/A from a year prior.
  • Shares Outstanding (Weighted Average) was $49.9 million for Q2 2025 at Theravance Biopharma, roughly flat from $49.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $76.3 million in Q2 2022 to a low of $48.3 million in Q1 2024.
  • A 5-year average of $61.0 million and a median of $60.1 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 18.9% in 2021, then fell 25.68% in 2023.
  • Theravance Biopharma's Shares Outstanding (Weighted Average) stood at $73.6 million in 2021, then increased by 0.02% to $73.6 million in 2022, then decreased by 22.15% to $57.3 million in 2023, then decreased by 14.73% to $48.8 million in 2024, then increased by 2.24% to $49.9 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Shares Outstanding (Weighted Average) are $49.9 million (Q2 2025), $49.7 million (Q1 2025), and $48.8 million (Q4 2024).